Taro Pharmaceutical Industries Ltd. (NYSE: TARO), relating to its proposed sale to Sun Pharmaceutical Industries Ltd. Under the terms of the agreement, TARO shareholders are expected to receive $43.00 in cash per share they own.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO), relating to its proposed sale to Sun Pharmaceutical Industries Ltd. Under the terms of the agreement, TARO shareholders are expected to receive $43.00 in cash per share they own.